Dr. Olszanski, Vice Chair of the Department of Medical Hematology and Oncology at Fox Chase Cancer Center, is the Director of the Early Clinical Drug Development Phase I Program and co-director of the Cutaneous Oncology Program. After Dr. Olszanski completed his hematology and oncology fellowship, he joined the phase I team at Dartmouth-Hitchcock Medical Center as a clinical pharmacology fellow. He is board certified in internal medicine, medical oncology, and clinical pharmacology. As a Director in Early Clinical Development at Pfizer, Dr. Olszanski gained invaluable pharmaceutical experience not only in early clinical and translational work, but also in late stage development. Dr. Olszanski focuses on the treatment of lung cancer and cutaneous malignancies, with a focus on melanoma. He sits on the NCCN Melanoma panel and the Management of Immunotherapy-Related Toxicities panel, providing expert input into the NCCN guidelines development, and frequently provides CME through the NCCN. He has written, developed, and run (or served as a sub-investigator on) many investigator-initiated trials. To date, at FCCC, Dr. Olszanski has served as the principal investigator on over 55 trials.